|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...4546474849505152535455...6768» |
- Trial completion, Post-transplantation: Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease (clinicaltrials.gov) - Jul 8, 2013
P1, N=12, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed
- letetresgene autoleucel (GSK3377794) / Adaptimmune
New P1/2 trial: CT Antigen TCR-Engineered T Cells for Myeloma (clinicaltrials.gov) - Jul 2, 2013
P1/2, N=10, Recruiting, Sponsor: Adaptimmune
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion, Metastases: Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation (clinicaltrials.gov) - Jul 2, 2013
P1/2, N=37, Completed, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador (clinicaltrials.gov) - Jul 1, 2013
P=N/A, N=81, Completed, Sponsor: Universidad del Azuay
Active, not recruiting --> Completed Recruiting --> Completed
- | PVX-410 / OncoPep
Enrollment open: Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma (clinicaltrials.gov) - Jul 1, 2013
P1/2, N=13, Recruiting, Sponsor: OncoPep, Inc.
Recruiting --> Completed Active, not recruiting --> Recruiting
- cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial completion: Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 1, 2013
P=N/A, N=52, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Ninlaro (ixazomib) / Takeda
Trial initiation date, Combination therapy: Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jun 30, 2013
P1/2, N=64, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed Initiation date: Jul 2011 --> Nov 2011
- TAK-901 / Takeda
Enrollment change, Metastases: A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies (clinicaltrials.gov) - Jun 30, 2013
P1, N=31, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Initiation date: Jul 2011 --> Nov 2011 N=65 --> 31
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment closed: Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 30, 2013
P1, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=65 --> 31 Recruiting --> Active, not recruiting
- | TAK-901 / Takeda
Trial completion, Metastases: A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies (clinicaltrials.gov) - Jun 30, 2013
P1, N=31, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Trial completion: UPFRONT: Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone (clinicaltrials.gov) - Jun 30, 2013
P3, N=502, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Metastases: Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction (clinicaltrials.gov) - Jun 30, 2013
P1, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Trial completion: Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Jun 30, 2013
P1, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial suspension: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (clinicaltrials.gov) - Jun 27, 2013
P2, N=38, Suspended, Sponsor: University of Medicine and Dentistry New Jersey
Active, not recruiting --> Completed Not yet recruiting --> Suspended
- Trial initiation date: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (clinicaltrials.gov) - Jun 27, 2013
P2, N=38, Suspended, Sponsor: University of Medicine and Dentistry New Jersey
Not yet recruiting --> Suspended Initiation date: Dec 2012 --> Jan 2014
- || pevonedistat (MLN4924) / Takeda
Enrollment change: Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma (clinicaltrials.gov) - Jun 27, 2013
P1, N=56, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Initiation date: Dec 2012 --> Jan 2014 N=88 --> 56
- | Enrollment open: UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma (clinicaltrials.gov) - Jun 26, 2013
P2, N=20, Recruiting, Sponsor: University of Arkansas
N=88 --> 56 Active, not recruiting --> Recruiting
- dexamethasone / Generic mfg., pomalidomide / Generic mfg.
P1 data: Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 26, 2013
P1, N=42, Not yet recruiting, Sponsor: New Mexico Cancer Care Alliance
- Enrollment change, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Jun 25, 2013
P=N/A, N=80, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Recruiting N=64 --> 80
- ||||||| bortezomib / Generic mfg.
Trial completion: A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 23, 2013
P3, N=217, Completed, Sponsor: Janssen-Cilag G.m.b.H
N=64 --> 80 Active, not recruiting --> Completed
- ||||||| bortezomib / Generic mfg.
Trial completion: Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 23, 2013
P3, N=154, Completed, Sponsor: Janssen-Cilag G.m.b.H
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P2 trial: UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma (clinicaltrials.gov) - Jun 20, 2013
P2, N=20, Recruiting, Sponsor: University of Arkansas
- || carfilzomib / Generic mfg.
Clinical: UARK 2009-32 Compassionate Use Study of Carfilzomib (clinicaltrials.gov) - Jun 20, 2013
P=N/A, N=140, Active, not recruiting, Sponsor: University of Arkansas
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- sapanisertib (CB-228) / Calithera
Trial initiation date: Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Jun 20, 2013
P1, N=39, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Initiation date: Jun 2010 --> Nov 2010
- melphalan / Generic mfg., lenalidomide / Generic mfg.
Trial termination: AMM-2011: Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma (clinicaltrials.gov) - Jun 19, 2013
P2, N=1, Terminated, Sponsor: University of Virginia
Initiation date: Jun 2010 --> Nov 2010 Recruiting --> Terminated; Study is no longer needed as recent data have answered the primary hypotheses for this study.
- melphalan / Generic mfg., lenalidomide / Generic mfg.
Enrollment change: AMM-2011: Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma (clinicaltrials.gov) - Jun 19, 2013
P2, N=1, Terminated, Sponsor: University of Virginia
Recruiting --> Terminated; Study is no longer needed as recent data have answered the primary hypotheses for this study. N=66 --> 1
- Enrollment change: Vitamin Deficiency and Blood Pressure in Hospitalized Jewish General Hospital (JGH) Patients (clinicaltrials.gov) - Jun 19, 2013
P2, N=50, Completed, Sponsor: Jewish General Hospital
N=66 --> 1 N=150 --> 50
- || dexamethasone injection / Generic mfg.
New P3 trial: All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Jun 18, 2013
P3, N=80, Recruiting, Sponsor: Shandong University
- Trial termination: International Registry and Biorepository for TMA(Thrombotic Microangiopathy) (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=6, Terminated, Sponsor: North Shore Long Island Jewish Health System
N=150 --> 50 Enrolling by invitation --> Terminated; study stopped at this site, as investigator left the institution
- Enrollment change: International Registry and Biorepository for TMA(Thrombotic Microangiopathy) (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=6, Terminated, Sponsor: North Shore Long Island Jewish Health System
Enrolling by invitation --> Terminated; study stopped at this site, as investigator left the institution N=60 --> 6
- fludarabine IV / Generic mfg.
Trial termination: Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies (clinicaltrials.gov) - Jun 17, 2013
P2/3, N=5, Terminated, Sponsor: University of Alabama at Birmingham
N=60 --> 6 Recruiting --> Terminated; Accrual goals could not be met within a timely manner
- fludarabine IV / Generic mfg.
Enrollment change: Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies (clinicaltrials.gov) - Jun 17, 2013
P2/3, N=5, Terminated, Sponsor: University of Alabama at Birmingham
Recruiting --> Terminated; Accrual goals could not be met within a timely manner N=45 --> 5
- Enrollment closed: A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma (clinicaltrials.gov) - Jun 16, 2013
P2, N=20, Active, not recruiting, Sponsor: New York University School of Medicine
N=45 --> 5 Suspended --> Active, not recruiting
- abexinostat (CG-781) / Xynomic
Enrollment change, Epigenetic controller: A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer (clinicaltrials.gov) - Jun 16, 2013
P1, N=7, Completed, Sponsor: Pharmacyclics
Suspended --> Active, not recruiting N=100 --> 7
- abexinostat (CG-781) / Xynomic
Trial completion, Epigenetic controller: A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer (clinicaltrials.gov) - Jun 16, 2013
P1, N=7, Completed, Sponsor: Pharmacyclics
N=100 --> 7 Active, not recruiting --> Completed
- Enrollment change: TOPIC: Transfusion of Fresh Frozen Plasma in Non-bleeding Intensive Care Unit (ICU) Patients (clinicaltrials.gov) - Jun 13, 2013
P=N/A, N=81, Completed, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Active, not recruiting --> Completed N=400 --> 81
- Trial completion: TOPIC: Transfusion of Fresh Frozen Plasma in Non-bleeding Intensive Care Unit (ICU) Patients (clinicaltrials.gov) - Jun 13, 2013
P=N/A, N=81, Completed, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
N=400 --> 81 Recruiting --> Completed
- GCS 100 IV / Innoviva
Trial termination: Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma (clinicaltrials.gov) - Jun 13, 2013
P1/2, N=9, Terminated, Sponsor: La Jolla Pharmaceutical Company
Recruiting --> Completed Suspended --> Terminated; Lack of funding
- GCS 100 IV / Innoviva
Enrollment change: Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma (clinicaltrials.gov) - Jun 13, 2013
P1/2, N=9, Terminated, Sponsor: La Jolla Pharmaceutical Company
Suspended --> Terminated; Lack of funding N=40 --> 9
- dinaciclib (MK-7965) / Merck (MSD)
Enrollment open, Combination therapy: Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Jun 13, 2013
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
N=40 --> 9 Not yet recruiting --> Recruiting
- ||| Promacta (eltrombopag) / Novartis
Enrollment change: LENS - Long-term Eltrombopag Observational Study (clinicaltrials.gov) - Jun 12, 2013
P2, N=164, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=350 --> 164
- |||| Promacta (eltrombopag) / Novartis
Trial completion: LENS - Long-term Eltrombopag Observational Study (clinicaltrials.gov) - Jun 12, 2013
P2, N=164, Completed, Sponsor: GlaxoSmithKline
N=350 --> 164 Active, not recruiting --> Completed
- Trial completion: Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) (clinicaltrials.gov) - Jun 11, 2013
P1/2, N=58, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- decitabine / Generic mfg.
Trial initiation date: A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia (clinicaltrials.gov) - Jun 11, 2013
P2, N=60, Recruiting, Sponsor: Shandong University
Active, not recruiting --> Completed Initiation date: Jun 2012 --> Jun 2013
- Enrollment change: S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 11, 2013
P2, N=147, Active, not recruiting, Sponsor: Southwest Oncology Group
Initiation date: Jun 2012 --> Jun 2013 N=99 --> 147
- decitabine / Generic mfg.
Enrollment open: A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia (clinicaltrials.gov) - Jun 11, 2013
P2, N=60, Recruiting, Sponsor: Shandong University
N=99 --> 147 Not yet recruiting --> Recruiting
- arsenic trioxide / Generic mfg.
Enrollment change: Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 9, 2013
P1/2, N=22, Completed, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Not yet recruiting --> Recruiting N=43 --> 22
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: RICH: Rituximab to Treat Severe Hemophilia A (clinicaltrials.gov) - Jun 6, 2013
P2, N=23, Completed, Sponsor: New England Research Institutes
N=43 --> 22 N=50 --> 23
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: RICH: Rituximab to Treat Severe Hemophilia A (clinicaltrials.gov) - Jun 6, 2013
P2, N=23, Completed, Sponsor: New England Research Institutes
N=50 --> 23 Active, not recruiting --> Completed
- ||||||| Acoalan (antithrombin gamma) / Kyowa Hakko Kirin
Trial completion: An Open-label Study of KW-3357 (clinicaltrials.gov) - Jun 3, 2013
P3, N=200, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
Active, not recruiting --> Completed Recruiting --> Completed